全球重要医学学术期刊《柳叶刀》杂志当地时间22日发表了中国21名科学家关于新型冠状病毒疫苗I期试验结果的论文。 We are all expecting a COVID-19 vaccine that could possibly end the pandemic that has killed more than 330,000 people. Now the first vaccine candidate from China has finished its phase-1 trial on humans, and the results have been put online for everyone to examine. The Lancet, a respected medical journal in the UK, published the results on Friday saying it is "safe" and "induces rapid immune response."
该论文的结论是：中国团队研究的全球首个重组腺病毒5型载体新冠疫苗通过安全性测试，并且能够诱导人体产生免疫反应。 军事科学院军事医学研究院生物工程研究所陈薇院士等人领衔的团队开展了这项临床试验。团队在试验中招募了108名健康的成年志愿者，年龄介于18岁至60岁。这些志愿者被分成不同组别接种了不同剂量的疫苗。 The research injected the potential vaccine into 108 volunteers. They were divided into three groups, each taking a different dose of the vaccine. The vaccine, classified as "recombinant adenovirus type-5 vectored" (Ad5-nCoV), acts as a natural infection and is especially good at teaching the immune system how to fight the virus. 报告显示，这108名志愿者在接种疫苗后第14天，中和抗体显著增加，并在接种后28天达到峰值；特异性T细胞反应在接种后第14天达到峰值。 此外，在接种后的28天内，这种疫苗在不同剂量的组别中都展示了很好的耐受性，没有引起严重不良反应。 During the next 28 days, no serious reactions were found, meaning the vaccine seemed to be tolerable by humans. Also, antibodies against the SARS-CoV-2 started to surge two weeks after the injection and reached its peak on day 28.
《柳叶刀》杂志主编理查德·霍顿通过社交媒体分享了这一进展。他表示，“这些研究结果象征着一个重要的里程碑。” 不过，陈薇指出，要谨慎对待相关成果。开发新冠病毒疫苗面临着前所未有的挑战，该项成果展示了疫苗开发的良好前景，但“我们离这种疫苗达到让所有人使用的阶段仍有较长的路要走”。 据《柳叶刀》介绍，开发出有效的疫苗是防控新冠疫情的长期解决方案。目前，全球有超过100种候选新冠病毒疫苗正在开发中。 The vaccine "warrants further investigation," the paper on The Lancet concluded. A phase-2 clinical trial has started with 508 volunteers involved. The trial was conducted by a team led by Chen Wei, a biology professor from Academy of Military Medical Sciences and a member of the Chinese Academy of Engineering. There are other two vaccines allowed for human trials in China. They are ShaCoVacc and PiCoVacc.